On this page

Nystatin and Triamcinolone Acetonide

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Nystatin and Triamcinolone Acetonide
Generic name
Nystatin and Triamcinolone Acetonide
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
21
Packages
40
Data completeness
83% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Nystatin 100000 [USP'U]/g 261178 View
Triamcinolone Acetonide 1 mg/g 1014314 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
61

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polyene Antifungal [EPC] EPC All 12 members
Polyenes [CS] CS All 13 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
208479
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 14, 2017
Sponsor
PADAGIS ISRAEL
Products on application
1
Submissions recorded
1
Products approved under application 208479.
Product Trade name Form Strength Ingredient Status TE Flags
208479-001 NYSTATIN AND TRIAMCINOLONE ACETONIDE CREAM NYSTATIN; TRIAMCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 208479.
Type No. Action Status Date Review
Original application 1 Approved August 14, 2017 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260112). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260112 HUMAN PRESCRIPTION DRUG · 20250707 HUMAN PRESCRIPTION DRUG · 20250408 HUMAN PRESCRIPTION DRUG · 20250120

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Nystatin and Triamcinolone Acetonide Cream is usually applied to the affected areas twice daily in the morning and evening by gently and thoroughly massaging the preparation into the skin. The cream should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). A thin film of Nystatin and Triamcinolone Acetonide Ointment is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). Nystatin and Triamcinolone Acetonide Cream and Ointment should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies. Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur. The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Crown Laboratories, Inc. at 1-423-926-4413 or FDA at 1-800-FDA-1088 or https://www.fda.gov/Safety/MedWatch/

Description

openFDA Drug Labeling

DESCRIPTION Nystatin and Triamcinolone Acetonide Cream, USP for dermatologic use contains the antifungal agent nystatin, USP and the synthetic corticosteroid triamcinolone acetonide, USP. Nystatin, USP is a polyene antimycotic obtained from Streptomyces noursei . It is a yellow to light tan, hygroscopic powder, having a bitter taste and an odor suggestive of cereals. It is freely soluble in dimethylformamide and dimethyl sulfoxide; slightly to sparingly soluble in methanol, n-propyl alcohol, and n-butyl alcohol; practically insoluble in water and alcohol; insoluble in chloroform and ether. Structural formula: C 47 H 75 NO 17 ; MW = 926.11 g/mol Triamcinolone acetonide, USP is designated chemically as pregna-1, 4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)-9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone. The white to cream colored, crystalline powder, having not more than a slight odor, is practically insoluble in water, sparingly soluble in dehydrated alcohol, in chloroform and in methanol. Structural formula: C 24 H 31 FO 6 ; MW = 434.50 g/mol Nystatin and Triamcinolone Acetonide Cream, USP is a soft, smooth yellow color cream. Each gram provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide, USP in a cream base with dried aluminum hydroxide gel, glyceryl monostearate, methylparaben, polyethylene glycol 400 monostearate, polyoxyl 20 cetostearyl ether, polysorbate-60, propylene glycol, propylparaben, purified water, simethicone emulsion, sorbic acid, sorbitol, titanium dioxide, and white petrolatum. nystatin-image triamcinolone-structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General) ; however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Nystatin and triamcinolone acetonide cream USP supplied in 15 gram, 30 gram and 60 gram tubes. 15 gram Tube NDC 33342-482-15 (1 tube per carton) 30 gram Tube NDC 33342-482-30 (1 tube per carton) 60 gram Tube NDC 33342-482-60 (1 tube per carton) STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid freezing. Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer by: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA Rev. 09/2023

Adverse event reports

Source: openFDA FAERS
31,697
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class III July 31, 2019 Lupin Pharmaceuticals Inc. Failed Content Uniformity Specifications: Out-of-specification result observed in uniformity of containers test at 9 month long term stability condition for upright orientation. Terminated
Class II April 26, 2017 Taro Pharmaceuticals U.S.A., Inc. Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
62332-606-15 62332-606 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-606-15) / 15 g in 1 TUBE April 2, 2021
62332-606-30 62332-606 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-606-30) / 30 g in 1 TUBE April 2, 2021
62332-606-60 62332-606 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-606-60) / 60 g in 1 TUBE April 2, 2021
46708-606-15 46708-606 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-606-15) / 15 g in 1 TUBE April 8, 2025
46708-606-30 46708-606 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-606-30) / 30 g in 1 TUBE April 8, 2025
46708-606-60 46708-606 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-606-60) / 60 g in 1 TUBE April 8, 2025
63629-8688-1 63629-8688 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8688-1) / 15 g in 1 TUBE November 27, 2017
63629-8689-1 63629-8689 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8689-1) / 30 g in 1 TUBE November 27, 2017
63629-8690-1 63629-8690 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8690-1) / 60 g in 1 TUBE November 27, 2017
71335-2894-1 71335-2894 Bryant Ranch Prepack 1 TUBE in 1 CARTON (71335-2894-1) / 30 g in 1 TUBE October 28, 2025
72162-1433-2 72162-1433 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1433-2) / 15 g in 1 TUBE March 11, 2024
72162-1433-3 72162-1433 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1433-3) / 30 g in 1 TUBE April 23, 2025
72162-1433-6 72162-1433 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1433-6) / 60 g in 1 TUBE March 11, 2024
0316-0223-15 0316-0223 Crown Laboratories 1 TUBE in 1 CARTON (0316-0223-15) / 15 g in 1 TUBE January 2, 2018
0316-0223-30 0316-0223 Crown Laboratories 1 TUBE in 1 CARTON (0316-0223-30) / 30 g in 1 TUBE January 2, 2018
0316-0223-60 0316-0223 Crown Laboratories 1 TUBE in 1 CARTON (0316-0223-60) / 60 g in 1 TUBE January 2, 2018
68462-314-17 68462-314 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-314-17) / 15 g in 1 TUBE October 25, 2016
68462-314-35 68462-314 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-314-35) / 30 g in 1 TUBE October 25, 2016
68462-314-65 68462-314 Glenmark Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68462-314-65) / 60 g in 1 TUBE October 25, 2016
68180-545-02 68180-545 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-545-02) / 30 g in 1 TUBE November 29, 2018
68180-545-03 68180-545 Lupin Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68180-545-03) / 60 g in 1 TUBE November 29, 2018
33342-482-15 33342-482 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-482-15) / 15 g in 1 TUBE August 31, 2022
33342-482-30 33342-482 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-482-30) / 30 g in 1 TUBE August 31, 2022
33342-482-60 33342-482 Macleods Pharmaceuticals Limited 1 TUBE in 1 CARTON (33342-482-60) / 60 g in 1 TUBE August 31, 2022
68071-3972-3 68071-3972 NuCare Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68071-3972-3) / 30 g in 1 TUBE March 2, 2026
68071-2491-3 68071-2491 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-2491-3) / 30 g in 1 TUBE August 4, 2021
68071-5037-3 68071-5037 NuCare Pharmaceuticals,Inc. 30 g in 1 TUBE (68071-5037-3) August 21, 2019
45802-880-14 45802-880 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-880-14) / 15 g in 1 TUBE November 27, 2017
45802-880-94 45802-880 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-880-94) / 30 g in 1 TUBE November 27, 2017
45802-880-96 45802-880 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-880-96) / 60 g in 1 TUBE November 27, 2017
68788-8662-3 68788-8662 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8662-3) / 30 g in 1 TUBE May 13, 2024
68788-8808-3 68788-8808 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8808-3) / 30 g in 1 TUBE January 20, 2025
68788-8245-3 68788-8245 Preferred Pharmaceuticals Inc., USA 1 TUBE in 1 CARTON (68788-8245-3) / 30 g in 1 TUBE August 18, 2022
70518-1114-0 70518-1114 REMEDYREPACK INC. 1 TUBE in 1 CARTON (70518-1114-0) / 30 g in 1 TUBE April 12, 2018
51672-1263-1 51672-1263 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1263-1) / 15 g in 1 TUBE December 22, 1987
51672-1263-2 51672-1263 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1263-2) / 30 g in 1 TUBE December 22, 1987
51672-1263-3 51672-1263 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1263-3) / 60 g in 1 TUBE December 22, 1987
13668-610-01 13668-610 Torrent Pharmaceuticals Limited 1 TUBE in 1 CARTON (13668-610-01) / 15 g in 1 TUBE July 14, 2020
13668-610-02 13668-610 Torrent Pharmaceuticals Limited 1 TUBE in 1 CARTON (13668-610-02) / 30 g in 1 TUBE July 14, 2020
13668-610-05 13668-610 Torrent Pharmaceuticals Limited 1 TUBE in 1 CARTON (13668-610-05) / 60 g in 1 TUBE July 14, 2020
62332-606 62332-606 Alembic Pharmaceuticals Inc. — April 2, 2021
46708-606 46708-606 Alembic Pharmaceuticals Limited — April 8, 2025
63629-8688 63629-8688 Bryant Ranch Prepack — November 27, 2017
63629-8689 63629-8689 Bryant Ranch Prepack — November 27, 2017
63629-8690 63629-8690 Bryant Ranch Prepack — November 27, 2017
71335-2894 71335-2894 Bryant Ranch Prepack — November 27, 2017
72162-1433 72162-1433 Bryant Ranch Prepack — November 27, 2017
0316-0223 0316-0223 Crown Laboratories — January 2, 2018
68462-314 68462-314 Glenmark Pharmaceuticals Inc., USA — October 24, 2016
68180-545 68180-545 Lupin Pharmaceuticals, Inc. — November 29, 2018
33342-482 33342-482 Macleods Pharmaceuticals Limited — August 31, 2022
68071-3972 68071-3972 NuCare Pharmaceuticals, Inc. — August 31, 2022
68071-2491 68071-2491 NuCare Pharmaceuticals,Inc. — November 27, 2017
68071-5037 68071-5037 NuCare Pharmaceuticals,Inc. — December 22, 1987
45802-880 45802-880 Padagis Israel Pharmaceuticals Ltd — November 27, 2017
68788-8662 68788-8662 Preferred Pharmaceuticals Inc. — May 13, 2024
68788-8808 68788-8808 Preferred Pharmaceuticals Inc. — January 20, 2025
68788-8245 68788-8245 Preferred Pharmaceuticals Inc., USA — August 18, 2022
70518-1114 70518-1114 REMEDYREPACK INC. — April 12, 2018
51672-1263 51672-1263 Sun Pharmaceutical Industries, Inc. — December 22, 1987
13668-610 13668-610 Torrent Pharmaceuticals Limited — July 14, 2020

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 13 sections on this page.